Last reviewed · How we verify

NCT04771637

Effect of Dexmedetomidine on Perioperative Internal Environment and Rehabilitation of Patients Undergoing Gastrointestinal Malignant Tumor Resection

Completed NA Last updated 30 November 2021
What this trial tests

NA trial testing Dexmedetomidine in Dexmedetomidine in 140 participants. Completed in 30 August 2020.

Timeline
1 January 2017
Primary endpoint
30 August 2020
30 August 2020

Quick facts

Lead sponsorYangzhou University
PhaseNA
StatusCompleted
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingquadruple
Primary purposetreatment
Enrollment140
Start date1 January 2017
Primary completion30 August 2020
Estimated completion30 August 2020
Sites1 location across China

Drugs / interventions tested

Conditions studied

Sponsor

Yangzhou University

Who can join

Adults 18 to 65, any sex, with Dexmedetomidine or Perioperative. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Dexmedetomidine is a highly selective alpha2-adrenergic receptor agonist with sedative, analgesic, anti-anxiety, and inhibitory sympathetic nerve excitation properties. It is commonly used in clinical anesthesia and intensive care.Radical gastrectomy for gastrointestinal malignant tumors is a common major operation in clinical practice, with long operation time, great trauma and strong stress response of patients. Dexmedetomidine is often used in general anesthesia during such operations, but its long-term use or large dose may produce certain side effects.Common side effects of dexmedetomidine include bradycardia and hypotension, etc. Previous studies have reported that dexmedetomidine can prolong QT interval and is at risk of causing tip torsion type ventricular tachycardia.Abnormal Potassium may affect myocardial repolarization and increase the risk of tip torsion ventricular tachycardia.The main purpose of this study was to observe the effects of long-term use of dexmedetomidine on perioperative internal environment such as electrolyte and rehabilitation indicators during radical general anesthesia for gastrointestinal malignancy, and the secondary purpose was to explore the optimal dose of dexmedetomidine for general anesthesia for patients undergoing radical general anesthesia for gastrointestinal malignancy.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

  1. Effects of Dexmedetomidine on Perioperative Serum Potassium and Postoperative Rehabilitation of Patients Undergoing Radical Resection of Gastrointestinal Malignancy
    Tian S, Zhang D, Wang Y, Yu L, et al · · 2021 · DOI 10.21203/rs.3.rs-1169113/v1

Verify or expand the search:

Other trials of Dexmedetomidine

Trials testing the same drug.

Other recruiting trials for Dexmedetomidine

Currently open trials in the same condition.

Other Yangzhou University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04771637.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing